OCTalks: TONIC-trial yields promising results for metastatic triple-negative breast cancer
Marleen Kok The Netherlands Cancer Institute (Amesterdam) presented the findings of the TONIC-trial recently at the ESMO 2017 Congress (8–12th September, Madrid, Spain), listen to the podcast now to discover all the details of the trial and Marleen’s favorite talks from ESMO.
In this podcast discover details of the TONIC-trial which has yielded promising response rates in patients with metastatic triple-negative breast cancer treated with nivolumab after induction treatment. This adaptive phase II randomized non-comparative trial allocated patients with metastatic TNBC who received ≤ 3 lines of palliative chemotherapy to one of five 2 week induction treatment arms consisting of either three cycles of 8 Gy irradiation of one metastatic lesion, or two cycles of doxorubicin at 15 mg weekly, or cyclophosphamide at 50 mg daily orally or two cycles of 40 mg/m2 of cisplatin, or to receive no induction treatment.
Related content:
IMpassion130: first positive Phase III immunotherapy study in TNBC
Oncolytic virotherapy before surgery sensitizes TNBC to checkpoint therapy
Infographic: Triple-negative breast cancer – the facts